Boston Scientific Drops 9% After Trial Results Boston Scientific slipped 9% on Mar 30, 2026 after a pivotal trial missed its primary endpoint, raising near-term guidance uncertainty and pressuring med-tech peers.

Boston Scientific Drops 9% After Trial Results: Boston Scientific slipped 9% on Mar 30, 2026 after a pivotal trial missed its primary endpoint, raising near-term guidance uncertainty and pressuring med-tech… 👈 Read full analysis #BostonScientific #MedTech #StockMarket #InvestmentNews #TrialResults

Viking Therapeutics stock falls after obesity drug trial results Investing.com -- Viking Therapeutics (NASDAQ:VKTX) stock fell 21% Tuesday morning despite announcing positive Phase 2 trial results for its oral obesity drug that showed significant weight loss in patients. The clinical-stage biopharmaceutical company reported that its Phase 2 VENTURE-Oral Dosing trial of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary and secondary endpoints. Patients receiving the once-daily oral tablet formulation demonstrated weight loss of up to 12.2% (26.6 lbs) after 13 weeks of treatment, compared to 1.3% (2.9 lbs) for those on placebo. The study showed a clear dose response across the treatment period, with weight loss being progressive at all doses through the 13-week study with no plateau observed. Up to 97% of subjects in the VK2735 treatment groups achieved at least 5% weight loss, compared with 10% for placebo, and up to 80% achieved at least 10% weight loss versus 5% for placebo. The company also reported that the drug was generally safe and well-tolerated, with 98% of drug-related treatment-emergent adverse events categorized as mild or moderate. The most common side effects were gastrointestinal, with nausea reported in 58% of participants receiving VK2735 compared to 48% for placebo. An exploratory dosing cohort designed to assess weight loss maintenance showed promising results. Patients rapidly titrated to 90 mg daily doses for four weeks and then down-titrated to 30 mg daily for seven weeks maintained their weight loss, suggesting that effective weight maintenance may be achieved at lower doses. Despite these positive results, investors appeared to react negatively to the news, sending Viking Therapeutics shares sharply lower in Tuesday trading. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year.. In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if VKTX is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.

Click Subscribe #VikingTherapeutics #StockMarket #Biotech #ObesityDrug #TrialResults

Incannex stock surges after positive sleep apnea trial results Investing.com -- Incannex Healthcare Inc. (NASDAQ:IXHL) stock jumped 10% Friday following the release of positive Phase 2 trial results for its obstructive sleep apnea (OSA) treatment, IHL-42X. The clinical-stage pharmaceutical company reported compelling efficacy data from its RePOSA Phase 2 trial, with patient exit interviews revealing that 57.6% of participants experienced perceived improvements in their OSA condition. Among those reporting benefits, 89.5% described the changes as meaningful to their daily lives. The trial demonstrated statistically significant improvements across multiple key endpoints. Patients receiving IHL-42X showed significant reductions in Apnoea-Hypopnoea Index (AHI) compared to placebo, with 41.2% of high-dose recipients achieving greater than 30% reduction in AHI. Some patients experienced AHI reductions of up to 83%. "Our recent Phase 2 results for IHL-42X exceeded expectations. In some patients, we observed reductions in AHI of up to 83%, which is an extraordinary outcome and a powerful signal of the drug’s potential," said Joel Latham, President and CEO of Incannex. The treatment also demonstrated an excellent safety profile with no serious adverse events reported during the treatment period. Most treatment-emergent adverse effects were mild or moderate. Patients reported improvements in sleep quality, reduced daytime sleepiness, fewer cognitive disturbances, and greater ease in completing daily responsibilities. Unlike many sleep medications, IHL-42X did not reduce REM sleep, an important stage for memory consolidation and brain health. The company remains well-capitalized to continue advancing its clinical programs while exploring strategic options to deliver long-term value to shareholders. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Incannex #StockMarket #Investing #SleepApnea #TrialResults

Protara Therapeutics stock drops following interim trial results Investing.com -- Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) tumbled 19% after the company released interim results from its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in patients with Non-Muscle Invasive Bladder Cancer (NMIBC). Despite demonstrating a 100% complete response rate at any time and a 67% 12-month landmark complete response rate in BCG-Unresponsive patients, investors appeared skeptical, leading to the stock’s decline. The trial’s interim data, presented at the American Urological Association 2025 Annual Meeting, showed promising efficacy and safety profiles for TARA-002, with no Grade 3 or greater treatment-related adverse events reported. The BCG-Naïve patient cohort also showed a 76% complete response rate at any time and a 43% 12-month landmark complete response rate. Analysts have weighed in on the results, with TD Cowen’s Stacy Ku, Ph.D., commenting, "TARA-002’s ~67% 12-month CRR in BCG-unresponsive NMIBC patients appear competitive, with a clean safety profile. Although early we are encouraged, as the efficacy looks promising. With solid patient enrollment progress, the key Phase II futility analysis for BCG-unresponsive patients is on-track for YE. The most significant opportunity for ’002 is NMIBC, with a high unmet need to avoid cystectomy." Cantor analyst Li Watsek also provided a positive outlook, stating, "The update from the Ph2 ADVANCED-2 of TARA-002 in NMIBC at AUA this weekend gave us greater confidence of a viable contender. Small N aside, any-time CR rate has improved to 100% from prior 80% in BCG-unresponsive patients. Importantly, the first look at the 12-mon CR rate of 67% compares well vs. ~50% benchmark set by CGON and JNJ." Despite the encouraging comments from analysts, the stock’s decline suggests that investors may have concerns about the small patient sample size and the generalizability of the results. The company is on track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025, which may provide further insights into the drug’s efficacy and potential market impact. Protara’s CEO Jesse Shefferman expressed confidence in the trial’s progress and the potential impact of TARA-002 for patients with NMIBC. The company aims to continue advancing the trial towards its goal of bringing transformative therapies to patients. However, the market’s reaction to the interim results indicates a cautious stance from investors at this stage of the drug’s development. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Is TARA truely undervalued? With TARA making headlines, investors are asking: Is it truly valued fairly? InvestingPro's advanced AI algorithms have analyzed TARA alongside thousands of other stocks to uncover hidden gems with massive upside. And guess what? TARA wasn't at the top of the list.

Click Subscribe #ProtaraTherapeutics #StockMarket #InvestingNews #PharmaStocks #TrialResults